BCL2L11 and non-small cell lung carcinoma: In the combined analysis of gene expression, copy number, and mutations in all of the 416 patients and 169 mutant EGFR patients who exhibited possible primary resistance, we found that 336 NSCLC patients (80.0%) carried at least one RG alteration (ALK, KRAS, BIM, PIK3CA, MET, IGF1R, and PTEN), and 35 patients (20.7%) harbored coexisting genetic alterations in the EGFR signaling pathway (KRAS, PIK3CA, and PTEN).